| pubmed-article:3219266 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3219266 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:3219266 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:3219266 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:3219266 | lifeskim:mentions | umls-concept:C0035020 | lld:lifeskim |
| pubmed-article:3219266 | lifeskim:mentions | umls-concept:C0312418 | lld:lifeskim |
| pubmed-article:3219266 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:3219266 | lifeskim:mentions | umls-concept:C0036667 | lld:lifeskim |
| pubmed-article:3219266 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:3219266 | pubmed:dateCreated | 1989-3-16 | lld:pubmed |
| pubmed-article:3219266 | pubmed:abstractText | The evolution of in vitro bone marrow clonogenic leukaemic cells (CFU-L) drug sensitivity was studied in 23 patients with acute myeloid leukaemia treated with anthracycline and cytosine arbinoside (ara-C). In 12 patients tested before and after first induction treatment failure (interval: 6 +/- 4 weeks), the sensitivity remained stable for daunorubicin and showed little variation for ara-C. Among eleven patients tested before treatment and at first relapse (interval: 13 +/- 7 months), in vitro CFU-L sensitivity revealed no correlation between the two measurements, and a trend in decreased sensitivity to daunorubicin and ara-C. These findings suggest that induction failures could be related to factors other than simple selection of a resistant CFU-L subclone. | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3219266 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3219266 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3219266 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3219266 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:3219266 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:3219266 | pubmed:author | pubmed-author:ZittounRR | lld:pubmed |
| pubmed-article:3219266 | pubmed:author | pubmed-author:MarieJ PJP | lld:pubmed |
| pubmed-article:3219266 | pubmed:author | pubmed-author:TheveninDD | lld:pubmed |
| pubmed-article:3219266 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3219266 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:3219266 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3219266 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3219266 | pubmed:pagination | 570-4 | lld:pubmed |
| pubmed-article:3219266 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:3219266 | pubmed:meshHeading | pubmed-meshheading:3219266-... | lld:pubmed |
| pubmed-article:3219266 | pubmed:meshHeading | pubmed-meshheading:3219266-... | lld:pubmed |
| pubmed-article:3219266 | pubmed:meshHeading | pubmed-meshheading:3219266-... | lld:pubmed |
| pubmed-article:3219266 | pubmed:meshHeading | pubmed-meshheading:3219266-... | lld:pubmed |
| pubmed-article:3219266 | pubmed:meshHeading | pubmed-meshheading:3219266-... | lld:pubmed |
| pubmed-article:3219266 | pubmed:meshHeading | pubmed-meshheading:3219266-... | lld:pubmed |
| pubmed-article:3219266 | pubmed:meshHeading | pubmed-meshheading:3219266-... | lld:pubmed |
| pubmed-article:3219266 | pubmed:meshHeading | pubmed-meshheading:3219266-... | lld:pubmed |
| pubmed-article:3219266 | pubmed:meshHeading | pubmed-meshheading:3219266-... | lld:pubmed |
| pubmed-article:3219266 | pubmed:meshHeading | pubmed-meshheading:3219266-... | lld:pubmed |
| pubmed-article:3219266 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3219266 | pubmed:articleTitle | In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia. | lld:pubmed |
| pubmed-article:3219266 | pubmed:affiliation | Service d'Hèmatologie de l'Hôtel-Dieu, Paris. | lld:pubmed |
| pubmed-article:3219266 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3219266 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
